AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Pulse Biosciences Statistics
Share Statistics
Pulse Biosciences has 61.52M shares outstanding. The number of shares has increased by 11.84% in one year.
Shares Outstanding | 61.52M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.37% |
Owned by Institutions (%) | n/a |
Shares Floating | 11.55M |
Failed to Deliver (FTD) Shares | 4.09K |
FTD / Avg. Volume | 2.43% |
Short Selling Information
The latest short interest is 2.17M, so 3.52% of the outstanding shares have been sold short.
Short Interest | 2.17M |
Short % of Shares Out | 3.52% |
Short % of Float | 18.77% |
Short Ratio (days to cover) | 11.05 |
Valuation Ratios
The PE ratio is -13.93 and the forward PE ratio is -19.71.
PE Ratio | -13.93 |
Forward PE | -19.71 |
PS Ratio | 0 |
Forward PS | 30.8 |
PB Ratio | 13.25 |
P/FCF Ratio | -17.73 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pulse Biosciences Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76, with a Debt / Equity ratio of 0.
Current Ratio | 6.76 |
Quick Ratio | 6.76 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -31.95 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -81.44%.
Return on Equity (ROE) | -0.95% |
Return on Assets (ROA) | -0.71% |
Return on Capital (ROIC) | -81.44% |
Revenue Per Employee | 0 |
Profits Per Employee | -753.75K |
Employee Count | 56 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 109.72% in the last 52 weeks. The beta is 1.75, so Pulse Biosciences 's price volatility has been higher than the market average.
Beta | 1.75 |
52-Week Price Change | 109.72% |
50-Day Moving Average | 18.09 |
200-Day Moving Average | 14.84 |
Relative Strength Index (RSI) | 43.67 |
Average Volume (20 Days) | 168.29K |
Income Statement
Revenue | n/a |
Gross Profit | -1.21M |
Operating Income | -43.57M |
Net Income | -42.21M |
EBITDA | -42.37M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.88 |
Balance Sheet
The company has 44.37M in cash and 9.14M in debt, giving a net cash position of 35.22M.
Cash & Cash Equivalents | 44.37M |
Total Debt | 9.14M |
Net Cash | 35.22M |
Retained Earnings | -336.92M |
Total Assets | 93.05M |
Working Capital | 73.67M |
Cash Flow
In the last 12 months, operating cash flow was -33.04M and capital expenditures -121.00K, giving a free cash flow of -33.16M.
Operating Cash Flow | -33.04M |
Capital Expenditures | -121.00K |
Free Cash Flow | -33.16M |
FCF Per Share | -0.69 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
PLSE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -5.1% |
FCF Yield | -3.12% |
Analyst Forecast
Currently there are no analyst rating for PLSE.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 44.46 |
Piotroski F-Score | 3 |